eMedicine Specialties > Neurology > Neuro-vascular Diseases

Fibromuscular Dysplasia

Author: James A Wilson, MD, MSc, FRCPC, BSc(H), Neurologist and Clinical Neurophysiologist, Oconee Neurology Services
Coauthor(s): Richard L Hughes, MD, Associate Professor, Department of Neurology, University of Colorado School of Medicine; Director, University of Colorado Affiliated Hospitals Stroke Project; Chief, Division of Neurology, Denver Health Medical Center
Contributor Information and Disclosures

Updated: Aug 30, 2007

Introduction

Background

Fibromuscular dysplasia (FMD) was first observed in 1938 by Leadbetter and Burkland in a 5-year-old boy, and described as a disease of the renal arteries. Involvement of the craniocervical arteries was recognized in 1946 by Palubinskas and Ripley.

FMD is an angiopathy that affects medium-sized arteries predominantly in young women of childbearing age. FMD most commonly affects the renal arteries and can cause refractory renovascular hypertension. Of patients with identified FMD, renal involvement occurs in 60-75%, cerebrovascular involvement occurs in 25-30%, visceral involvement occurs in 9%, and arteries of the limbs are affected in about 5%.1,2 Case reports have shown FMD in most other medium-to-large arteries as well, including the coronary arteries3 , the pulmonary arteries4 , and the aorta5 . In 26% of patients, disease is found in more than one arterial region6 .

In patients with identified cephalic FMD, 95% have internal carotid artery involvement and 12-43% have vertebral artery involvement. Although FMD can affect arteries of any size7 , involvement of smaller ones, including intracranial vessels, is rare. Although an early autopsy series of 819 consecutive patients found the prevalence of FMD in the internal carotid arteries to be 1%8 , a larger, more recent autopsy series of 20,244 patients recently identified the overall prevalence of FMD of the internal carotid arteries to be only 0.02%9 . From a neurologic perspective, FMD is an important cause of stroke in young adults.

Pathophysiology

The etiology of FMD is not known, although the histopathologic findings have been described in detail (see Histologic Findings).

Although the etiology of FMD is unknown, several other associated vascular pathologies have been identified. In 1982, Mettinger and Ericson10 scrutinized 4000 consecutively performed cerebral angiographies and found 37 that were consistent with FMD. Of these, 19 patients had aneurysms. In 1988, Cloft et al performed a meta-analysis including 498 FMD patients as well as examined 117 of their own patients and found a combined prevalence of aneurysms to be 7.3%.11

In 1975, Stanley et al found that 8 of their 17 cerebrovascular FMD cases had intracranial aneurysms, and they proposed a classification system that includes a "medial fibroplasias with aneurysms" subtype.12 The beadlike dilatations observed within FMD lesions share gross and histologic characteristics of aneurysms. The casual link between FMD and aneurysms is less clear but is possibly related to an underlying connective tissue problem that results in loss of arterial wall strength. This wall weakness may allow for vessel dilation (aneurysm formation and beading in FMD) as well as injury, which then causes compensatory fibroplasia. Besides aneurysms, many case series and reports have identified FMD in patients presenting with arterial dissection.13,14

FMD is a predisposing factor in 15% of spontaneous cervical carotid dissections (Saver, 1998). Dissections in FMD are more commonly multiple than in patients without an identified underlying arteriopathy.

FMD lesions likely predispose the artery to dissection through weakening of the arterial wall. Although the multiple manifestations of a structural arteriopathy in FMD hint of a genetic cause, such as collagen or elastin mutation, epidemiologic data suggesting familial transmission are generally weak.

The increased incidence of FMD in women as compared with men suggests a possible hormonal or genetic influence. Some authors have proposed the sex difference to be related to immune system functioning, but overt inflammation, as is observed in most classic autoimmune diseases, is histologically lacking.

Many reports exist of familial occurrences of FMD, mostly in siblings. Some studies have even suggested that familial occurrence is relatively common. For example, Rushton in 1980 suggested familial occurrences in relatives of 12 out of 20 identified probands.15 However, histologic proof was established in only the index cases, and vascular events such as early strokes and hypertension were used to identify the other affected family members. Most large series have reported that the great preponderance of FMD cases are sporadic. Bilateral renal FMD has been noted in a pair of identical twins.16

In case reports, FMD has been associated with mutations in collagen17 , with cutis laxa18 , and with alpha1-antitrypsin deficiency19 . Associative links to neurofibromatosis, Alport syndrome, and pheochromocytoma have also been suggested.2

Frequency

United States

Although early autopsy and radiologic series suggested that FMD involving the craniocervical arteries occurs at a frequency of approximately 1%, a more recent large series looking at FMD in the carotid arteries only suggests a lower frequency, on the order of 0.02%.9

International

The frequency is unknown.

Mortality/Morbidity

FMD generally follows a benign course and is frequently an incidental finding. However, cranial involvement bears worse prognosis because of the occurrence of dissection and strokes and the coexistence of saccular aneurysms. Specific mortality and morbidity data are lacking. 

Regarding the risk of recurrent carotid artery dissection, de Bray et al prospectively reviewed 103 consecutive patients with carotid artery dissection with follow-up for an average of 4 years. Of those, 5 had recurrent dissections and 4 of the 5 patients with recurrent dissections were diagnosed with FMD. If considering the presentation of recurrent dissection of the carotid artery, FMD was associated in 80% of their series.20

Race

Whites are considered to be more commonly affected than blacks, although specific statistics on racial predilection are not available.

Sex

FMD occurs more frequently in women, at a ratio of approximately 3:1 to 4:1.

Age

FMD most commonly presents in young to middle-aged adults. One angiographic series found a mean age of 48 years with a range of 24-70 years.10 Cases have even been described in the pediatric population, including infantile-onset cases.21

Clinical

History

Most patients with craniocervical FMD are asymptomatic. Others report nonspecific problems such as headache, lightheadedness, vertigo, and tinnitus. Neck pain or carotidynia may be an initial presenting symptom due to arterial dissection. The symptoms of stroke can be varied but most often involve the anterior circulation because of the predilection of FMD to affect the extracranial carotid arteries.

Patients may provide a history of transient or permanent neurologic deficits of the face or extremities such as weakness or numbness, or they may experience visual changes or speech difficulties. No particular symptoms are pathognomonic for FMD, and any history compatible with a stroke in younger individuals may indicate underlying FMD. The family history should include information about relatives who have had vascular events at a young age.

One report notes an extremely unfortunate case of locked-in syndrome due to autopsy-proven basilar artery FMD.13 FMD may be complicated by stroke because of direct effects of craniocervical stenosis, dissection, or intracranial aneurysm, or the indirect effects of concomitant renovascular hypertension.

Symptoms compatible with a sentinel bleed, namely a sudden explosive headache followed later by neck stiffness, may signify the existence of an aneurysm, which in turn, may be associated with FMD.

A review of symptoms may provide clues of noncraniocervical FMD. Long-standing involvement of the renal arteries may lead to a history of hypertension. Rarely, abdominal pains, and even a history of ischemic bowel, may indicate mesenteric or visceral artery involvement. Vascular compromise of the limbs by FMD lesions may cause ischemic symptoms such as intermittent leg claudication.

Physical

Because of the broad possibilities of neurologic dysfunction due to stroke caused by FMD, a thorough neurologic examination should be performed. Findings may include anything from cranial nerve deficits to weakness, numbness, and coordination difficulties.

Sensitive signs of motor dysfunction such as pronator drift and plantar responses may yield deficits when formal power assessment does not. The neurovascular examination would not be complete without auscultation for carotid and vertebral artery bruits. If a headache history is provided, assessment for meningismus (eg, nuchal rigidity, Kernig sign, Brudzinski sign) may prove positive.

Because of the systemic nature of FMD, the general physical examination should include a search for signs of renal, visceral, and limb arterial involvement. These signs may include hypertension, decreased peripheral pulses, and even asymmetric limb pressures. Bruits may be found on auscultation of the renal, abdominal, iliac, or subclavian arteries.

Causes

The cause of FMD is unknown, despite some speculations related to its associations with some rare genetic conditions and predilection for young white females. Strokes can be caused by the FMD stenoses themselves, generally by thromboembolic events. Even without trauma, FMD lesions predispose the afflicted individual to arterial dissection, which in turn can cause embolic events or, rarely, local thrombosis and massive hemispheric stroke. Hypertension due to renovascular FMD may be a risk factor for lacunar and large vessel infarcts and even intracerebral hemorrhage.

More on Fibromuscular Dysplasia

Overview: Fibromuscular Dysplasia
Differential Diagnoses & Workup: Fibromuscular Dysplasia
Treatment & Medication: Fibromuscular Dysplasia
Follow-up: Fibromuscular Dysplasia
Multimedia: Fibromuscular Dysplasia
References

References

  1. Luscher TF, Lie JT, Stanson AW, et al. Arterial fibromuscular dysplasia. Mayo Clin Proc. Oct 1987;62(10):931-52. [Medline].

  2. Gray GH, Young JR, Olin JW. Miscellaneous arterial diseases. In: Young JR, Olin JW, Bartholomew J, eds. Peripheral Vascular Diseases. 2nd ed. St Louis: Mosby-Yearbook; 1996:425-40.

  3. James TN. Morphologic characteristics and functional significance of focal fibromuscular dysplasia of small coronary arteries. Am J Cardiol. Apr 3 1990;65(14):12G-22G. [Medline].

  4. Campman SC, Holmes JF, Sokolove PE, et al. Pulmonary arterial fibromuscular dysplasia: a rare cause of fulminant lunghemorrhage. Am J Forensic Med Pathol. Mar 2000;21(1):69-73. [Medline].

  5. Maresi E, Becchina G, Ottoveggio G, et al. Arrhythmic sudden cardiac death in a 3-year-old child with intimal fibroplasia of coronary arteries, aorta, and its branches. Cardiovasc Pathol. Jan-Feb 2001;10(1):43-8. [Medline].

  6. Luscher TF, Keller HM, Imhof HG, et al. Fibromuscular hyperplasia: extension of the disease and therapeutic outcome. Results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia. Nephron. 1986;44 Suppl 1:109-14. [Medline].

  7. Hill LD, Antonius JI. Arterial dysplasia: an important surgical lesion. Arch Surg. Apr 1965;90:585-95. [Medline].

  8. Heffelfinger MJ, Holley KE, Havrison EG. Arterial fibromuscular dysplasia studied at autopsy [abstract]. Am J Clin Pathol. 1970;54:274.

  9. Schievink WI, Bjornsson J. Fibromuscular dysplasia of the internal carotid artery: a clinicopathological study. Clin Neuropathol. Jan-Feb 1996;15(1):2-6. [Medline].

  10. Mettinger KL, Ericson K. Fibromuscular dysplasia and the brain. I. Observations on angiographic, clinical and genetic characteristics. Stroke. Jan-Feb 1982;13(1):46-52. [Medline].

  11. Cloft HJ, Kallmes DF, Kallmes MH, et al. Prevalence of cerebral aneurysms in patients with fibromuscular dysplasia:a reassessment. J Neurosurg. Mar 1998;88(3):436-40. [Medline].

  12. Stanley JC, Gewertz BL, Bove EL, et al. Arterial fibrodysplasia. Histopathologic character and current etiologic concepts. Arch Surg. May 1975;110(5):561-6. [Medline].

  13. Arunodaya GR, Vani S, Shankar SK, et al. Fibromuscular dysplasia with dissection of basilar artery presenting as "locked-in-syndrome". Neurology. Jun 1997;48(6):1605-8. [Medline].

  14. Eachempati SR, Sebastian MW, Reed RL 2nd. Posttraumatic bilateral carotid artery and right vertebral artery dissections in a patient with fibromuscular dysplasia: case report and review of the literature. J Trauma. Feb 1998;44(2):406-9. [Medline].

  15. Rushton AR. The genetics of fibromuscular dysplasia. Arch Intern Med. Feb 1980;140(2):233-6. [Medline].

  16. Bigazzi R, Bianchi S, Quilici N, et al. Bilateral fibromuscular dysplasia in identical twins. Am J Kidney Dis. Dec 1998;32(6):E4. [Medline].

  17. Tromp G, Wu Y, Prockop DJ, et al. Sequencing of cDNA from 50 unrelated patients reveals that mutations inthe triple-helical domain of type III procollagen are an infrequent causeof aortic aneurysms. J Clin Invest. Jun 1993;91(6):2539-45. [Medline].

  18. McKusick VA. Heritable Disorders of Connective Tissue. 4th ed. St Louis: Mosby-Yearbook; 1972:382-6.

  19. Schievink WI, Meyer FB, Parisi JE, Wijdicks EF. Fibromuscular dysplasia of the internal carotid artery associated with alpha1-antitrypsin deficiency. Neurosurgery. Aug 1998;43(2):229-33; discussion 233-4. [Medline].

  20. de Bray JM, Marc G, Pautot V, Vielle B, Pasco A, Lhoste P. Fibromuscular dysplasia may herald symptomatic recurrence of cervical artery dissection. Cerebrovasc Dis. 2007;23(5-6):448-52. [Medline].

  21. Lee EK, Hecht ST, Lie JT. Multiple intracranial and systemic aneurysms associated withinfantile-onset arterial fibromuscular dysplasia. Neurology. Mar 1998;50(3):828-9. [Medline].

  22. Mettinger KL. Fibromuscular dysplasia and the brain. II. Current concept of the disease. Stroke. Jan-Feb 1982;13(1):53-8. [Medline].

  23. de Monyé C, Dippel DW, Dijkshoorn ML, Tanghe HL, van der Lugt A. MDCT detection of fibromuscular dysplasia of the internal carotid artery. AJR Am J Roentgenol. April 2007;188(4):W367-9. [Medline].

  24. Sabharwal R, Vladica P, Coleman P. Multidetector spiral CT renal angiography in the diagnosis of renal artery fibromuscular dysplasia. Eur J Radiol. March 2007;61(3):520-7. [Medline].

  25. Willoteaux S, Faivre-Pierret M, Moranne O, Lions C, Bruzzi J, Finot M, et al. Fibromuscular dysplasia of the main renal arteries: comparison of contrast-enhanced MR angiography with digital subtraction angiography. Radiology. December 2006;241(3):922-9. [Medline].

  26. Bragin MA, Cherkasov AP. [Morphogenesis of fibromuscular dysplasia of the renal arteries (anultrastructural study)]. Arkh Patol. 1979;41(2):46-52. [Medline].

  27. Harrison EG Jr, McCormack LJ. Pathologic classification of renal arterial disease in renovascular hypertension. Mayo Clin Proc. Mar 1971;46(3):161-7. [Medline].

  28. Begelman SM, Olin JW. Fibromuscular dysplasia. Curr Opin Rheumatol. Jan 2000;12(1):41-7. [Medline].

  29. Reiher L, Pfeiffer T, Sandmann W. Long-term results after surgical reconstruction for renal artery fibromuscular dysplasia. Eur J Vasc Endovasc Surg. Dec 2000;20(6):556-9. [Medline].

  30. Van Damme H, Sakalihasan N, Limet R. Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review. Acta Chir Belg. Aug 1999;99(4):163-8. [Medline].

  31. Chiche L, Bahnini A, Koskas F, Kieffer E. Occlusive fibromuscular disease of arteries supplying the brain: results of surgical treatment. Ann Vasc Surg. Sep 1997;11(5):496-504. [Medline].

  32. Collins GJ Jr, Rich NM, Clagett GP, et al. Fibromuscular dysplasia of the internal carotid arteries. Clinical experience and follow-up. Ann Surg. Jul 1981;194(1):89-96. [Medline].

  33. Finsterer J, Strassegger J, Haymerle A, Hagmüller G. Bilateral stenting of symptomatic and asymptomatic internal carotid artery stenosis due to fibromuscular dysplasia. J Neurol Neurosurg Psychiatry. Nov 2000;69(5):683-6. [Medline].

  34. Leadbetter WF, Burkland CD. Hypertension in unilateral renal disease. J Urol. 1938;39:611-26.

  35. Leary MC, Finley A, Caplan LR. Cerebrovascular Complications of Fibromuscular Dysplasia. Curr Treat Options Cardiovasc Med. Jun 2004;6(3):237-248. [Medline].

  36. Palubinskas AJ, Ripley HR. Fibromuscular hyperplasia in extrarenal arteries. Radiology. 1946;82:451-55.

  37. Vuong PN, Desoutter P, Mickley V. Fibromuscular dysplasia of the renal artery responsible for renovascular hypertension: a histological presentation based on a series of 102 patients. Vasa. Feb 2004;33(1):13-8. [Medline].

Further Reading

Keywords

FMD, fibromuscular hyperplasia, medial hyperplasia, arterial fibrodysplasia, angiopathy, renal artery disease, stroke

Contributor Information and Disclosures

Author

James A Wilson, MD, MSc, FRCPC, BSc(H), Neurologist and Clinical Neurophysiologist, Oconee Neurology Services
James A Wilson, MD, MSc, FRCPC, BSc(H) is a member of the following medical societies: American Academy of Neurology and Ontario Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Richard L Hughes, MD, Associate Professor, Department of Neurology, University of Colorado School of Medicine; Director, University of Colorado Affiliated Hospitals Stroke Project; Chief, Division of Neurology, Denver Health Medical Center
Richard L Hughes, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, American Medical Association, and North American Neuro-Ophthalmology Society
Disclosure: Nothing to disclose.

Medical Editor

Jeffrey L Saver, MD, Director, Stroke Center, Professor, Department of Neurology, University of California at Los Angeles Medical Center
Jeffrey L Saver, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, American Neurological Association, and National Stroke Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Howard S Kirshner, MD, Professor of Neurology, Psychiatry and Hearing and Speech Sciences, Vice Chairman, Department of Neurology, Vanderbilt University School of Medicine; Director, Vanderbilt Stroke Center; Program Director, Stroke Service, Vanderbilt Stallworth Rehabilitation Hospital; Consulting Staff, Department of Neurology, Nashville Veterans Affairs Medical Center
Howard S Kirshner, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, American Heart Association, American Medical Association, American Neurological Association, American Society of Neurorehabilitation, National Stroke Association, Phi Beta Kappa, and Tennessee Medical Association
Disclosure: Boehringer Ingelheim Honoraria Speaking and teaching; BMS/Sanofi Honoraria Speaking and teaching; Pfizer Honoraria Speaking and teaching; Novartis Consulting fee Review panel membership

CME Editor

Selim R Benbadis, MD, Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, University of South Florida School of Medicine, Tampa General Hospital
Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Helmi L Lutsep, MD, Associate Professor, Department of Neurology, Oregon Health and Science University; Associate Director, Oregon Stroke Center
Helmi L Lutsep, MD is a member of the following medical societies: American Academy of Neurology and American Stroke Association
Disclosure: Co-Axia Consulting fee Review panel membership; Talecris Consulting fee Review panel membership; AGA Medical Consulting fee Review panel membership; Boehringer Ingelheim Honoraria Speaking and teaching; Boston Scientific Honoraria Speaking and teaching

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.